Side-by-side comparison of AI visibility scores, market position, and capabilities
Nov 2025: Q3 revenue $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA (European telehealth)
Hims & Hers is a telehealth platform offering personalized healthcare and wellness products for conditions like hair loss, sexual health, mental health, skincare, and primary care through online consultations and direct-to-consumer delivery. The company serves individuals seeking convenient, affordable, and discreet access to prescription medications and wellness products without traditional doctor visits. Hims & Hers has disrupted traditional healthcare delivery by combining telemedicine, pharmacy services, and branded wellness products in a consumer-friendly platform that reduces stigma and barriers to care for sensitive health concerns.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.